The fast pace of innovation in IT offers compelling investment opportunities
Truffle Capital is a pioneer investor in the exciting field of Energy
Biotechnology has radically transformed medicine over the past 25 years
Deinove Appoints Julien Coste as Director of Finance & Administration
Paris, July 31st, 2012 – Deinove (Alternext Paris: ALDEI), the green technology company and world specialist in the development of deinococcus bacteria for the production of bioethanol and green chemistry, today announces the appointment of Julien Coste as Director in charge of Finance and Administration. Julien will be based in Deinove’s facilities in Montpellier and his appointment strengthens Deinove’s management team.
Julien has extensive experience in senior management, having worked for both private, young innovative companies and publicly traded global corporations. Notably, he was Director of Finance and Administration at Neuro3d, a biotechnology start-up firm based in Mulhouse. More recently, he held the same position for the French branch of Publicis Healthcare Communications Group (PHCG), a division of the Publicis Group.
Julien has a Masters’ degree in Management from ESC Grenoble as well as a Masters’ degree in Information Systems from the University of Paris Dauphine. He is a national of both France and the United States.
Jacques Biton, Chief Executive Officer of Deinove, in welcoming Julien, stated: “We are delighted that Julien is joining the management team of Deinove, his breadth of experience and commitment will be of great value during the next phase of the company’s development and growth. His international outlook complements the skill base of the existing team and reinforces Deinove’s ambition to become a recognized global leader in its field”.
Deinove (Alternext Paris: ALDEI) is a green technology company specialized in the development and commercial exploitation of innovative, environmentally friendly, high-performance processes for production of biofuels and other compounds of industrial or pharmaceutical value. The processes developed by the company use bacteria with exceptional natural properties – the Deinococci. The company’s business strategy is to leverage its proprietary bacterial strains, technologies and processes by out-licensing to industrial partners. Deinove has partnered with leading sugar, ethanol and starch company TEREOS in order to develop the Deinol project, which aims at producing cellulosic ethanol in existing industrial facilities. Deinove currently has 30 staff and operates several collaborative R&D programmes with the CNRS (Montpellier and Marseille), the University of Paris V, INSA Toulouse and the VTT-Technical Research Centre of Finland.
It was incorporated in late 2006 under the joint impetus of Philippe Pouletty, MD (Managing Partner at the private equity firm Truffle Capital) and Professor Miroslav Radman (Professor of Cell Biology at Paris-Descartes University, a member of the French Academy of Science and winner of the 2003 INSERM Medical Research Prize). Professor Radman elucidated the genetic mechanism behind the extraordinary natural properties of the bacterium Deinococcus (biodiversity and robustness) on which Deinove’s innovation strategy is based. The company’s headquarters are in Paris and it operates a lab in Montpellier (Cap Alpha Technopark), southern France. Deinove is listed on Alternext since April 2010. For more detailed information visit the company’s website at: www.deinove.com
ALIZE RP DEINOVE
Caroline Carmagnol Elisabetta Castelli
CEO Director of Communications
Té: +33(0)1 42 68 86 43 / +33(0)6 64 18 99 59 Tel: +33 (0)1 42 03 27 37